Medicare coverage for VEVYE (daxasamide) is not currently available. As of now, VEVYE is not on the list of covered drugs under Medicare Part D [1].
Will Medicare Ever Cover VEVYE?
The availability of Medicare coverage for VEVYE may change in the future. Drug coverage decisions by Medicare are influenced by various factors, including therapeutic value, cost-effectiveness, and market availability. However, there is no current indication of when or if VEVYE might be added to Medicare's list of covered drugs [1].
What Is VEVYE Used For?
VEVYE, with the active ingredient daxasamide, is a prescription medication approved to treat generalized pustular psoriasis (GPP) in adults [1]. GPP is a rare, severe form of psoriasis characterized by widespread pustules on the skin [2].
What Are the Costs of VEVYE Without Insurance?
The cost of VEVYE can be significant for individuals without insurance coverage. A typical 30-day supply of VEVYE may cost around $7,000 or more [3]. This high cost can be a barrier for patients who need access to the medication.
Are There Patient Assistance Programs for VEVYE?
For individuals facing financial challenges in affording VEVYE, there are patient assistance programs that may help. These programs can offer financial support to eligible patients, reducing their out-of-pocket expenses [3]. Information on these programs is typically available through the drug manufacturer or specialized patient support services.
How Does VEVYE Work?
VEVYE functions by targeting specific inflammatory pathways involved in GPP. It works by modulating certain immune responses that contribute to the development of pustules and inflammation in GPP [1].
What Are the Side Effects of VEVYE?
Common side effects associated with VEVYE include nausea, diarrhea, abdominal pain, and upper respiratory tract infections. Patients are advised to discuss potential side effects and any concerns with their healthcare provider [1].
What Is the Difference Between VEVYE and Other Psoriasis Treatments?
VEVYE is specifically indicated for generalized pustular psoriasis, a distinct and severe form of the disease. Many other psoriasis treatments are designed for plaque psoriasis or other types and may not be as effective or appropriate for GPP. The mechanism of action of VEVYE is also targeted towards the specific inflammatory processes of GPP [1, 2].
What Are the Approved Treatments for Generalized Pustular Psoriasis?
Besides VEVYE, other treatments for generalized pustular psoriasis may include systemic therapies like retinoids, cyclosporine, or biologics, depending on the severity and individual patient factors. Treatment decisions are made by healthcare professionals based on a comprehensive evaluation of the patient's condition [2].
Sources:
[1] DrugPatentWatch.com
[2] https://www.aad.org/media/news-release/fda-approves-first-treatment-generalized-pustular-psoriasis
[3] https://www.vevye.com/